Les biothérapies dans le lupus érythémateux disséminé et tes connectivites: nouvelles thérapeutiques [Treatment of connective tissue diseases with biological agents]

Détails

ID Serval
serval:BIB_A2F09A5B399F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Les biothérapies dans le lupus érythémateux disséminé et tes connectivites: nouvelles thérapeutiques [Treatment of connective tissue diseases with biological agents]
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
So A.
ISSN
1660-9379
Statut éditorial
Publié
Date de publication
2008
Volume
4
Numéro
149
Pages
707-708, 710
Langue
français
Résumé
As B-cells are crucial for the production of antibodies and also in antigen presentation, they can play an important role in autoimmune connective tissue disease. B-cell surface antigens and receptors which are capable of activating B-cell function have been proposed as targets for therapy in these diseases. Anti-B cell treatments have been used recently in SLE and primary Sjogren's syndrome in a number of open studies, notably anti-CD20 (rituximab), with encouraging results. An anti-BAFF antibody (belimumab) has been tested in patients with SLE and also showed positive results in patients with increased levels of autoantibodies. In contrast, anti-TNF therapy in connective tissue disease and in RA can increase the levels of autoantibodies. Further studies are needed to define the place of these novel treatments in the management of autoimmune connective tissue diseases.
Mots-clé
Anti-Inflammatory Agents, Antibodies, Monoclonal, Connective Tissue Diseases, Humans, Immunologic Factors
Pubmed
Création de la notice
29/01/2009 23:14
Dernière modification de la notice
20/08/2019 16:08
Données d'usage